Press Release


Teknova to Participate in Upcoming Investor Conferences

February 10, 2023 at 8:00 AM EST

HOLLISTER, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conferences:

BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
February 14 - 16, 2023
Snowbird, UT

Cowen 43rd Annual Health Care Conference
March 6 - 8, 2023
Boston, MA
Fireside Chat: Wednesday, March 8, 2023, at 2:10 p.m. EST

Stephen Gunstream, Teknova’s President and Chief Executive Officer, and Matt Lowell, Teknova’s Chief Financial Officer, plan to discuss Company highlights, their product portfolio, market trends, key growth drivers, and long-term market opportunities.

A live audio webcast from the Cowen 43rd Annual Health Care Conference may be accessed from the Investor Relations section of the Company’s website: Webcasts are available on the Company’s website for approximately 90 days after each event.

About Teknova  
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 400,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.


Investor Contacts Matt Lowell Chief Financial Officer +1 831-637-1100 Sara Michelmore MacDougall Advisors +1 781-235-3060 Media Contact Jennifer Henry Senior Vice President, Marketing +1 831-313-1259